In recent trading session, Acrivon Therapeutics Inc (NASDAQ:ACRV) saw 0.52 million shares changing hands at last check today with its beta currently measuring 1.59. Company’s recent per share price level of $1.23 trading at $0.13 or 11.82% at last check today assigns it a market valuation of $38.57M. That most recent trading price of ACRV’s stock is at a discount of -726.02% from its 52-week high price of $10.16 and is indicating a premium of 11.38% from its 52-week low price of $1.09.
For Acrivon Therapeutics Inc (ACRV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Acrivon Therapeutics Inc (NASDAQ:ACRV) trade information
Upright in the green today for gaining 11.82%, in the last five days ACRV remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $1.23 price level, adding 3.53% to its value on the day. Acrivon Therapeutics Inc’s shares saw a change of -79.57% in year-to-date performance and have moved 6.03% in past 5-day. Acrivon Therapeutics Inc (NASDAQ:ACRV) showed a performance of -33.51% in past 30-days.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 93.85% to its recent value today. Analysts have been projecting 17 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -1282.11% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1282.11% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -74.96% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 3.64% while estimates for its earnings growth in next 5 years are of 1.64%.
Acrivon Therapeutics Inc (NASDAQ:ACRV)’s Major holders
RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at ACRV for having 8.34 million shares of worth $48.37 million. And as of 2024-06-30, it was holding 23.083 of the company’s outstanding shares.
The second largest institutional holder is PERCEPTIVE ADVISORS LLC, which was holding about 5.36 million shares on 2024-06-30. The number of shares represents firm’s hold over 14.8366 of outstanding shares, having a total worth of $31.09 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 407.49 shares of worth $0.49 million or 1.30% of the total outstanding shares. The later fund manager was in possession of 287.4 shares on Mar 31, 2025 , making its stake of worth around $0.35 million in the company or a holder of 0.92% of company’s stock.
